United Therapeutics Other — Gross Profit increased by 8.1% to -$6.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 580.0%, from -$1.00M to -$6.80M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals improved profitability or better cost control in secondary segments, whereas a decrease or negative value highlights potential financial strain or high investment costs in these areas.
This metric represents the profit remaining from the non-core business segments after deducting the direct costs of prod...
Similar to 'Segment Gross Profit' reported by diversified companies, providing insight into the margin profile of non-core business units.
uthr_segment_other_gross_profit| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $10.00M | $0.00 | $0.00 | -$600.00K | -$1.40M | -$2.30M | -$2.20M | -$1.20M | -$1.80M | -$300.00K | -$1.50M | -$1.00M | -$1.50M | -$4.10M | -$7.40M | -$6.80M |
| QoQ Change | — | — | — | — | -100.0% | — | — | -133.3% | -64.3% | +4.3% | +45.5% | -50.0% | +83.3% | -400.0% | +33.3% | -50.0% | -173.3% | -80.5% | +8.1% |
| YoY Change | — | — | — | — | — | — | -106.0% | — | — | — | -100.0% | -28.6% | +87.0% | +31.8% | +16.7% | +16.7% | <-999% | -393.3% | -580.0% |